The development of a new bioartificial liver and its application in 12 acute liver failure patients

Table 1 Clinical data of the patients

Patient No.	Sex	Age	Hepatitis B infection	Regimen of treatment	Number of treatment	Result
1	M	13	+	HBAL (CC)	1	Improved
2	M	38	+	1. HBAL (BAC)	1	Improved
				2. BAL	1
3	F	34	+	HBAL (BAC)	1	Improved
4	M	55	+	HBAL (BAC)	1	Death
5	M	52	+	HBAL (BAC)	1	Improved
6	M	46	+	HBAL (BAC)	1	Improved
7	M	58	+	HBAL (BAC)	1	Improved
8	M	33	+	PE and BAL	1	Improved
9	F	50	+	PE and BAL	2	Death
10	F	52	+	HF and BAL	1	Death
11	M	40	+	HF and BAL	1	Improved
12	M	30	+	BAC and BAL	1	Improved

M: Male, F: Female, +: Positive, HBAL: Hybrid bioartificial liver, BAL: Bioartificial liver, (CC): With charcoal column, (BAC): With bilirubin absorption column, PE and BAL: Plasma exchange and 24 hours later BAL only, HF and BAL: Hemofiltration and 24 hours later BAL only, BAC and BAL: Bilirubin absorption and 24 hours later BAL only.